Cisplatin Resistance Associated with PARP Hyperactivation
Published version of a preprint
Abstract
Non–small cell lung carcinoma patients are frequently treated with cisplatin (CDDP), most often yielding temporary clinical responses. Here, we show that PARP1 is highly expressed and constitutively hyperactivated in a majority of human CDDP-resistant cancer cells of distinct histologic origin. Cells manifesting elevated intracellular levels of poly(ADP-ribosyl)ated proteins (PARhigh) responded to pharmacologic PARP inhibitors as well as to PARP1-targeting siRNAs by initiating a DNA damage response that translated into cell death following the activation of the intrinsic pathway of apoptosis. Moreover, PARP1-overexpressing tumor cells and xenografts displayed elevated levels of PAR, which predicted the response to PARP inhibitors in vitro and in vivo more accurately than PARP1 expression itself. Thus, a majority of CDDP-resistant cancer cells appear to develop a dependency to PARP1, becoming susceptible to PARP inhibitor–induced apoptosis. Cancer Res; 73(7); 2271–80. ©2013 AACR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mitotic catastrophe is a major mechanism of action of anticancer chemotherapeutics, reflecting increased resistance of neoplastic cells to intrinsic apoptosis.
“However, mitotic catastrophe appears to constitute a major mechanism of action of anticancer chemotherapeutics, mostly reflecting the increased resistance of neoplastic cells to the induction of intrinsic apoptosis [1004–1009].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [1005]
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,708 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525 · see citing works
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598 · see citing works
Self-citationMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · see citing works
Self-citationGalluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421 · see citing works
Self-citationAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819 · see citing works
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765 · see citing works
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655 · see citing works
Amé, J., Spenlehauer, C., & de MURCIA, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,463 · see citing works
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311 · see citing works
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · see citing works
(ADP-ribose)n participates in DNA excision repair
Durkacz, B. W., Omidiji, O., Gray, D. A., & Shall, S. (1980) · Nature · doi:10.1038/283593a0 · Cited by 1,123 · see citing works
Fong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,009 · see citing works
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 857 · see citing works
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes
Galluzzi, L., Aaronson, S. A., Abrams, J., Alnemri, E. S., Andrews, D. W., Baehrecke, E. H., Bazan, N. G., Blagosklonny, M. V., Blomgren, K., Borner, C., et al. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.44 · Cited by 698 · see citing works
Self-citationStructural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Langelier, M.-F., Planck, J. L., Roy, S., & Pascal, J. M. (2012) · Science · doi:10.1126/science.1216338 · Cited by 669 · see citing works
Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615 · see citing works
Cell death assays for drug discovery
Kepp, O., Galluzzi, L., Lipinski, M. M., Yuan, J., & Kroemer, G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3373 · Cited by 556 · see citing works
Self-citationCombining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies
Bretz, F., Pinheiro, J. C., & Branson, M. (2005) · Biometrics · doi:10.1111/j.1541-0420.2005.00344.x · Cited by 399 · see citing works
Plummer, R., Jones, C., Middleton, M. R., Wilson, R. H., Evans, J., Olsen, A. L., Curtin, N. J., Boddy, A. V., McHugh, P. J., Newell, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 386 · see citing works
Regulation of autophagy by the inositol trisphosphate receptor
Criollo, A., Maiuri, M. C., Tasdemir, E., Vitale, I., Fiebig, A. A., Andrews, D. W., Molgó, J., Dı́az, J., Lavandero, S., Harper, F., et al. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402099 · Cited by 305 · see citing works
Self-citationStröm, C. E., Johansson, F., Uhlén, M., Szigyarto, C. A., Erixon, K., & Helleday, T. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1241 · Cited by 297 · see citing works
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286 · see citing works
Ossovskaya, V., Koo, I. C., Kaldjian, E. P., Alvares, C., & Sherman, B. M. (2010) · Genes & Cancer · doi:10.1177/1947601910383418 · Cited by 271 · see citing works
Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function
Chang, P., Coughlin, M. L., & Mitchison, T. J. (2005) · Nature Cell Biology · doi:10.1038/ncb1322 · Cited by 259 · see citing works
Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases
Ba, X., & Garg, N. J. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.004 · Cited by 211 · see citing works
Structure and function of poly(ADP-ribose) polymerase
de MURCIA, G., Schreiber, V., Molinete, M., Saulier, B., Poch, O., Masson, M., Niedergang, C., & Murcia, J. M. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928438 · Cited by 208 · see citing works
Delaney, C. A., Wang, L. Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomský, Z., & Newell, D. R. (2000) · PubMed · doi:10.25405/ncl.34597155 · Cited by 205 · see citing works
XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks
Horton, J. K., Watson, M., Stefanick, D. F., Shaughnessy, D. T., Taylor, J. A., & Wilson, S. H. (2008) · Cell Research · doi:10.1038/cr.2008.7 · Cited by 198 · see citing works
Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos
Vitale, I., Senovilla, L., Jemaà, M., Michaud, M., Galluzzi, L., Kepp, O., Nanty, L., Criollo, A., Rello‐Varona, S., Manic, G., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.11 · Cited by 146 · see citing works
Self-citationPrognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.017 · Cited by 133 · see citing works
Self-citationThe potential of exploiting DNA-repair defects for optimizing lung cancer treatment
Postel-Vinay, S. C., Vanhecke, E., Olaussen, K. A., Lord, C. J., Ashworth, A., & Soria, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.3 · Cited by 113 · see citing works
Self-citationHoffmann, J., Vitale, I., Buchmann, B., Galluzzi, L., Schwede, W., Senovilla, L., Skuballa, W., Vivet, S., Lichtner, R. B., Vicencio, J. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0237 · Cited by 103 · see citing works
Self-citationMitochondrial control of cell death induced by hyperosmotic stress
Criollo, A., Galluzzi, L., Maiuri, M. C., Tasdemir, E., Lavandero, S., & Kroemer, G. (2006) · APOPTOSIS · doi:10.1007/s10495-006-0328-x · Cited by 96 · see citing works
Self-citationPoly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Annunziata, C. M., & O’Shaughnessy, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0526 · Cited by 95 · see citing works
Daniel, R. A., Rozanska, A. L., Thomas, H. D., Mulligan, E. A., Drew, Y., Castelbuono, D. J., Hostomský, Z., Plummer, E. R., Boddy, A. V., Tweddle, D. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1095 · Cited by 84 · see citing works
Kameoka, M., Nukuzuma, S., Itaya, A., Tanaka, Y., Ota, K., Ikuta, K., & Yoshihara, K. (2004) · Journal of Virology · doi:10.1128/jvi.78.16.8931-8934.2004 · Cited by 78 · see citing works
Zaremba, T., Ketzer, P., Cole, M. F., Coulthard, S. A., Plummer, E. R., & Curtin, N. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605166 · Cited by 73 · see citing works
Clark, C. C., Weitzel, J. N., & O'Connor, T. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0597 · Cited by 63 · see citing works
Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy
Plummer, E. R., & Calvert, H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0617 · Cited by 56 · see citing works
PARP Cleavage as a Means of Assessing Apoptosis
Mullen, P. (2003) · Humana Press eBooks · doi:10.1385/1-59259-406-9:171 · Cited by 54 · see citing works
Regulatory mechanisms of poly(ADP-ribose) polymerase.
Álvarez-González, R., Watkins, T. A., Gill, P., Reed, J. L., & Mendoza‐Alvarez, H. (1999) · PubMed · Cited by 30 · see citing works
Regulatory mechanisms of poly(ADP-ribose) polymerase
Álvarez-González, R., Watkins, T. A., Gill, P. K., Reed, J. L., & Mendoza‐Alvarez, H. (1999) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006979220009 · Cited by 24 · see citing works
Berger, N. A. (1995) · Biochimie · doi:10.1016/0300-9084(96)88147-8 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works
Self-citationModulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579 · see citing works
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782 · see citing works
Self-citationThe multifaceted role of reactive oxygen species in tumorigenesis
Kirtonia, A., Sethi, G., & Garg, M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03536-5 · Cited by 452 · see citing works
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
Fennell, D. A., Summers, Y., Cadranel, J. L., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren‐Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382 · see citing works
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Yamazaki, T., Kirchmair, A., Sato, A., Buqué, A., Rybstein, M., Petroni, G., Bloy, N., Finotello, F., Stafford, L., Navarro Manzano, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0751-0 · Cited by 359 · see citing works
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Sautès‐Fridman, C., Tartour, É., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 327 · see citing works
Self-citationAdvances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 335 · see citing works
Trial watch: STING agonists in cancer therapy
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777624 · Cited by 289 · see citing works
Self-citationMolecular mechanisms of regulated necrosis
Galluzzi, L., Kepp, O., Krautwald, S., Kroemer, G., & Linkermann, A. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.02.006 · Cited by 258 · see citing works
Self-citationTrial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239 · see citing works
Self-citationTrapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230 · see citing works
Chloroquine and hydroxychloroquine for cancer therapy
Manic, G., Obrist, F., Kroemer, G., Vitale, I., & Galluzzi, L. (2014) · Molecular & Cellular Oncology · doi:10.4161/mco.29911 · Cited by 231 · see citing works
Self-citationRadiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 215 · see citing works
Self-citationSensitivity and resistance to treatment in the primary management of epithelial ovarian cancer
Colombo, P., Fabbro, M., Theillet, C. G., Bibeau, F., Rouanet, P., & Ray-Coquard, I. L. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.017 · Cited by 188 · see citing works
Trial watch: IDO inhibitors in cancer therapy
Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 188 · see citing works
Self-citationImmunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175 · see citing works
Self-citationTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162 · see citing works
Self-citationThe role of DNA repair pathways in cisplatin resistant lung cancer
O’Grady, S., Finn, S. P., Cuffe, S. D., Richard, D. J., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.003 · Cited by 149 · see citing works
Rodriguez-Ruiz, M. E., Buqué, A., Hensler, M., Chen, J., Bloy, N., Petroni, G., Sato, A., Yamazaki, T., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655964 · Cited by 147 · see citing works
Self-citationTrial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
Manic, G., Obrist, F., Sistigu, A., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1012976 · Cited by 147 · see citing works
Self-citationBiomarkers of Response and Resistance to DNA Repair Targeted Therapies
Stover, E. H., Konstantinopoulos, P. A., Matulonis, U. A., & Swisher, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0247 · Cited by 146 · see citing works
Tufo, G., Jones, A. W. E., Wang, Z., Hamelin, J., Tajeddine, N., Esposti, D. D., Martel, C., Boursier, C., Gallerne, C., Migdal, C., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.193 · Cited by 131 · see citing works
Self-citationCurrent status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 130 · see citing works
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 134 · see citing works
Metabolic vulnerability of cisplatin‐resistant cancers
Obrist, F., Michels, J., Durand, S., Chery, A., Pol, J. G., Lévesque, S., Joseph, A., Astesana, V., Pietrocola, F., Wu, G. S., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201798597 · Cited by 122 · see citing works
Self-citationPARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
Swindall, A. F., Stanley, J. A., & Yang, E. S.-H. (2013) · Cancers · doi:10.3390/cancers5030943 · Cited by 117 · see citing works
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 113 · see citing works
Self-citationPredictive biomarkers for cancer therapy with PARP inhibitors
Michels, J., Vitale, I., Saparbaev, M. K., Castedo, M., & Kroemer, G. (2013) · Oncogene · doi:10.1038/onc.2013.352 · Cited by 113 · see citing works
Self-citationImmunotherapy in Cervical Cancer
Mauricio, D., Zeybek, B., Tymon‐Rosario, J., Harold, J. A., & Santin, A. D. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01052-8 · Cited by 112 · see citing works
PARP1 Inhibitors: Antitumor Drug Design
Maluchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., & Studitskiy, V. M. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-3-27-37 · Cited by 111 · see citing works
Cheng, H., Zhang, Z., Barrueco, R. R., Borczuk, A., Liu, H., Yu, J., Silva, J. M., Cheng, S. K., Perez-Soler, R., & Halmos, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6721 · Cited by 93 · see citing works
Wu, X., Dong, Z., Wang, C. J., Barlow, L., Fako, V. E., Serrano, M. A., Zou, Y., Liu, J., & Zhang, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609934113 · Cited by 93 · see citing works
Extracorporeal photochemotherapy induces bona fide immunogenic cell death
Tatsuno, K., Yamazaki, T., Hanlon, D. J., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F. E., Arshad, N., Edelson, R. L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1819-3 · Cited by 89 · see citing works
Self-citationOxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities
Wang, M., Xiao, Y.-P., Miao, J., Zhang, X., Liu, M., Zhu, L., Liu, H., Shen, X., Wang, J.-H., Xie, B., et al. (2025) · Antioxidants · doi:10.3390/antiox14060735 · Cited by 104 · see citing works
Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13232-3 · Cited by 84 · see citing works
Profile of veliparib and its potential in the treatment of solid tumors
Wagner, L. M. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s69935 · Cited by 78 · see citing works
Michel, L. S., Dyroff, S. L., Brooks, F. J., Spayd, K. J., Lim, S., Engle, J. T., Phillips, S. E., Tan, B. R., Wang‐Gillam, A., Bognar, C., et al. (2016) · Radiology · doi:10.1148/radiol.2016161929 · Cited by 78 · see citing works
Fischer, C., Leithner, K., Wohlkoenig, C., Quehenberger, F., Bertsch, A., Olschewski, A., Olschewski, H., & Hrzenjak, A. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-4 · Cited by 77 · see citing works
Yarchoan, M. M., Myzak, M. C., Johnson, B. A., Jesus‐Acosta, A. D., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 77 · see citing works
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
Michels, J., Vitale, I., Senovilla, L., Enot, D. P., Garcia, P., Lissa, D., Olaussen, K. A., Brenner, C., Soria, J., Castedo, M., et al. (2013) · Cell Cycle · doi:10.4161/cc.24034 · Cited by 74 · see citing works
Self-citationApproach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B
El‐Senduny, F. F., Badria, F. A.-E., El‐Waseef, A. M., Chauhan, S. C., & Halaweish, F. T. (2015) · Tumor Biology · doi:10.1007/s13277-015-3773-8 · Cited by 73 · see citing works
Bertrand, B., Fernández‐Cestau, J., Angulo, J., Cominetti, M. M. D., Waller, Z. A. E., Searcey, M., O'Connell, M. A., & Bochmann, M. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b00339 · Cited by 73 · see citing works
Duan, S., Tsai, Y., Keng, P., Chen, Y., Lee, S. O., & Chen, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4753 · Cited by 72 · see citing works
The Evolution of STING Signaling and Its Involvement in Cancer
Vashi, N., & Bakhoum, S. F. W. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.12.010 · Cited by 70 · see citing works
Wang, H., Shan, Z., Song, L., Qu, M., & Zou, Z. (2020) · Oncogene · doi:10.1038/s41388-020-1191-x · Cited by 69 · see citing works
MCL-1 dependency of cisplatin-resistant cancer cells
Michels, J., Obrist, F., Vitale, I., Lissa, D., Garcia, P., Behnam‐Motlagh, P., Kohno, K., Wu, G. S., Brenner, C., Castedo, M., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.029 · Cited by 68 · see citing works
Self-citationThe Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
Reinbolt, R. E., & Hays, J. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00237 · Cited by 62 · see citing works
C‐Jun N‐terminal kinase signalling pathway in response to cisplatin
Yan, D., An, G., & Kuo, M. T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12908 · Cited by 61 · see citing works
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair
Choi, E.-B., Yang, A.-Y., Kim, S. C., Lee, J., Choi, J. K., Choi, C., & Kim, M. Y. (2016) · Oncogene · doi:10.1038/onc.2016.3 · Cited by 59 · see citing works
Natural Product Modulators to Overcome Multidrug Resistance In Cancer
Çört, A., & Özben, T. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1002624 · Cited by 56 · see citing works
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
Caiola, E., Salles, D. C., Frapolli, R., Lupi, M., Rotella, G., Ronchi, A., Garassino, M. C., Mattschas, N. A. L., Colavecchio, S., Broggini, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5019 · Cited by 52 · see citing works
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
Lu, Y., Liu, Y., Pang, Y. K., Pacák, K., & Yang, C. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.006 · Cited by 51 · see citing works
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Yusoh, N. A., Ahmad, H., & Gill, M. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000391 · Cited by 52 · see citing works
A Double-Edged Sword: The Two Faces of PARylation
Kang, M., Park, S., Park, S., Lee, H. G., & Park, J. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179826 · Cited by 46 · see citing works
Investigational drugs for the treatment of cervical cancer
Barra, F., Lorusso, D., Maggiore, U. L. R., Ditto, A., Bogani, G., Raspagliesi, F., & Ferrero, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1302427 · Cited by 46 · see citing works
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
Wangpaichitr, M., Theodoropoulos, G., Nguyen, D. J. M., Wu, C., Spector, S. A., Feun, L. G., & Savaraj, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147379 · Cited by 44 · see citing works
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
Eskander, R. N., & Tewari, K. S. (2014) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2014.25.3.249 · Cited by 42 · see citing works
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 44 · see citing works
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib
Bianchi, A., Lopez, S., Altwerger, G. H., Bellone, S., Bonazzoli, E., Zammataro, L. A., Manzano, A., Manara, P., Perrone, E., Zeybek, B., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.08.010 · Cited by 42 · see citing works
Cisplatin in the era of PARP inhibitors and immunotherapy
Duan, M., Leng, S., & Mao, P. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108642 · Cited by 44 · see citing works
DNA repair and the contribution to chemotherapy resistance
Nesic, K., Parker, P., Swisher, E. M., & Krais, J. J. (2025) · Genome Medicine · doi:10.1186/s13073-025-01488-8 · Cited by 50 · see citing works
MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1
Luo, Y.-S., Tong, L., Meng, H., Zhu, W., Guo, L., Wei, T., & Zhang, J. (2016) · Gene · doi:10.1016/j.gene.2016.11.031 · Cited by 41 · see citing works
The oncolytic peptide LTX-315 triggers necrotic cell death
Forveille, S., Zhou, H., Sauvat, A., Bezu, L., Müller, K., Liu, P., Zitvogel, L., Pierron, G., Rekdal, Ø., Kepp, O., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1093710 · Cited by 39 · see citing works
Self-citationSourisseau, T., Hélissey, C., Lefèbvre, C., Ponsonnailles, F., Malka-Mahieu, H., Olaussen, K. A., André, F., Vagner, S., & Soria, J. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1120918 · Cited by 36 · see citing works
Self-citationLorusso, D., Tripodi, E., Maltese, G., Lepori, S., Sabatucci, I., Bogani, G., & Raspagliesi, F. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s124447 · Cited by 37 · see citing works
Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold
Giannini, G., Battistuzzi, G., Vesci, L., Milazzo, F. M., Paolis, F. D., Barbarino, M., Guglielmi, M. B., Carollo, V., Gallo, G., Artali, R., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.048 · Cited by 36 · see citing works
Alemasova, E. E., Naumenko, K. N., Kurgina, T. A., Anarbaev, R. O., & Lavrik, O. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25158 · Cited by 35 · see citing works
Karyotypic Aberrations in Oncogenesis and Cancer Therapy
Vitale, I., Manic, G., Senovilla, L., Kroemer, G., & Galluzzi, L. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.08.001 · Cited by 34 · see citing works
Self-citationDual Approaches in Oncology: The Promise of siRNA and Chemotherapy Combinations in Cancer Therapies
Sousa, C., & Videira, M. (2025) · Onco · doi:10.3390/onco5010002 · Cited by 34 · see citing works
PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
Mann, M., Kumar, S., Sharma, A. K., Chauhan, S. S., Bhatla, N., Kumar, S., Bakhshi, S., Gupta, R., & Kumar, L. (2019) · Oncotarget · doi:10.18632/oncotarget.27008 · Cited by 34 · see citing works
Quantification of cellular viability by automated microscopy and flow cytometry
Sauvat, A., Wang, Y., Segura, F., Spaggiari, S., Müller, K., Zhou, H., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Oncotarget · doi:10.18632/oncotarget.3266 · Cited by 32 · see citing works
Self-citationSingh, V. K., Arora, D., Satija, N. K., Khare, P., Roy, S. K., & Sharma, P. K. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1404-0 · Cited by 31 · see citing works
Wang, Q., Xiong, J., Qiu, D., Zhao, X. B., Yan, D., Xu, W., Wang, Z., Chen, Q., Panday, S., Li, A., et al. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.08.001 · Cited by 31 · see citing works
Zhao, W., You, C., Zhuang, J., Zu, J., Chi, Z., Xu, G., & Yan, J. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1740-5 · Cited by 30 · see citing works
Xie, K., He, H., Sun, A., Liu, X.-B., Sun, L. L., & Dong, X.-J. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.6.2591 · Cited by 30 · see citing works
Michels, J., Adam, J., Goubar, A., Obrist, F., Damotte, D., Robin, A., Alifano, M., Vitale, I., Olaussen, K. A., Girard, P., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv393 · Cited by 30 · see citing works
Self-citationFatima, I., Ayachi, I. E., Playa, H. C., Alva-Ornelas, J. A., Khalid, A. B., Kuenzinger, W. L., Wend, P., Pence, J. C., Brakefield, L., Krutilina, R. I., et al. (2019) · Cancers · doi:10.3390/cancers11122039 · Cited by 30 · see citing works
Cervical cancer: a tale from HPV infection to PARP inhibitors
Mann, M., Singh, V. P., & Kumar, L. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.09.014 · Cited by 31 · see citing works
Targeted drug conjugate systems for ovarian cancer chemotherapy
Ogundipe, O. D., Olajubutu, O., & Adesina, S. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115151 · Cited by 29 · see citing works
Evaluation of the methods to identify patients who may benefit from PARP inhibitor use
Lim, D. G. S., & Ngeow, J. Y. Y. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0116 · Cited by 28 · see citing works
Systems biology approaches to develop innovative strategies for lung cancer therapy
Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.28 · Cited by 27 · see citing works
MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance
Wang, J., Kho, D., Zhou, J.-Y., Davis, R. J., & Wu, G. S. (2017) · Oncogene · doi:10.1038/onc.2017.197 · Cited by 28 · see citing works
Self-citationLiu, Y., Wang, Y., Guan, X., Wu, Q., Zhang, M., Cui, P., Wang, C., Chen, X., Meng, X., & Ma, T. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05374 · Cited by 27 · see citing works
Wolford, J. E., & Tewari, K. S. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1443074 · Cited by 27 · see citing works
Pivetta, T., Lallai, V., Valletta, E., Trudu, F., Isaia, F., Perra, D., Pinna, E., & Pani, A. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.05.004 · Cited by 27 · see citing works
Chemotherapy for advanced gastric cancer: future perspective in Japan
Shitara, K. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0648-7 · Cited by 26 · see citing works
Ming-xin, C., Wang, H., Niu, J., Song, Y., & Zou, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.610205 · Cited by 26 · see citing works
Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer
Shitara, K., & Ohtsu, A. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0138 · Cited by 25 · see citing works
Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition?
Tomao, F., Santangelo, G., Musacchio, L., Donato, V. D., Fischetti, M., Giancotti, A., Perniola, G., Petrella, M. C., Monti, M., Palaia, I., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29440 · Cited by 26 · see citing works
Rational design of anticancer platinum(IV) prodrugs
Zhang, S., Wang, X., & Guo, Z. (2019) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2019.10.009 · Cited by 25 · see citing works
Elemental bioimaging of Cisplatin inCaenorhabditis elegansby LA-ICP-MS
Crone, B., Aschner, M., Schwerdtle, T., Kärst, U., & Bornhorst, J. (2015) · Metallomics · doi:10.1039/c5mt00096c · Cited by 25 · see citing works
Trial watch – inhibiting PARP enzymes for anticancer therapy
Sistigu, A., Manic, G., Obrist, F., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1053594 · Cited by 24 · see citing works
Self-citationSingh, M. P., Khaket, T. P., Bajpai, V. K., Alfarraj, S. A., Kim, S.-G., Chen, L., Huh, Y. S., Han, Y.-K., & Kang, S. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218253 · Cited by 24 · see citing works
Lombardi, A. J., Hoskins, E. E., Foglesong, G. D., Wikenheiser‐Brokamp, K. A., Wiesmüller, L., Hanenberg, H., Andreassen, P. R., Jacobs, A. J., Olson, S. B., Keeble, W. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2616 · Cited by 23 · see citing works
Shuhendler, A. J., Cui, L., Chen, Z., Shen, B., Chen, M., James, M. L., Witney, T. H., Bazalova‐Carter, M., Gambhir, S. S., Chin, F. T., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00089 · Cited by 23 · see citing works
Wan, Q., Shen, Y., Zhao, H., Wang, B., Zhao, L., Zhang, Y., Bu, X., Wan, M., & Shen, C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27703 · Cited by 22 · see citing works
Nunno, V. D., Frega, G., Santoni, M., Gatto, L., Fiorentino, M., Montironi, R., Battelli, N., Brandi, G., & Massari, F. (2019) · Future Oncology · doi:10.2217/fon-2018-0915 · Cited by 22 · see citing works
Zhang, F., Shen, M., Li, Y., Yang, X., Tsai, Y., Keng, P. C., Chen, Y., Lee, S. O., & Chen, Y. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1345391 · Cited by 22 · see citing works
Drugging cancer metabolism: Expectations vs. reality
Montrose, D. C., & Galluzzi, L. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.007 · Cited by 21 · see citing works
Self-citation
- Authors
- Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., Talbot, M., Robin, A., Girard, P., Oréar, C., Lissa, D., Sukkurwala, A. Q., Garcia, P., Behnam-Motlagh, P., Kohno, K., Wu, G. S., Brenner, C., Dessen, P., Saparbaev, M., Soria, J.-C., Castedo, M., & Kroemer, G.
- Affiliations
- Université Paris-Sud (FR)
- Authors' Affiliations: 1U848, 2U981, 3U985, INSERM; 4Institut Gustave Roussy; 5Université Paris Sud; 6UMR8200, CNRS; Plateformes de 7Bioinformatique, 8Génomique, and 9Metabolomique, Institut Gustave Roussy; Villejuif; 10Université Paris Descartes; 11Department of Thoracic Oncology, Institut Mutualiste Montsouris; 12Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers; 13Pôle de Biologie, Hôpital Européen Georges Pompidou AP-HP, Paris; 14U769, INSERM-LabEx LERMIT, Université Paris-Sud, Châtenay Malabry, France; 15Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden; 16Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu/Fukuoka, Japan; and 17Molecular Therapeutics Program, Karmanos Cancer Institute, Department of Oncology and Pathology, Wayne State University School of Medicine, Detroit, Michigan
- ORCID
- Venue
- Cancer Research
- Published
- 2013-04-01
- Volume
- 73
- Issue
- 7
- Pages
- 2271-2280
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2060534647
- Cited by
- 176
- References
- 47
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 10 · 2023: 10 · 2022: 11 · 2021: 15 · 2020: 14 · 2019: 12 · 2018: 13 · 2017: 15 · 2016: 17 · 2015: 19 · 2014: 18 · 2013: 8
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- cisplatin resistance, PARP1, PARP inhibitors, non-small cell lung cancer, DNA damage response, mitochondrial apoptosis, poly(ADP-ribosyl)ation, siRNA knockdown, xenografts, chemoresistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Mice, Nude, Phenanthrenes, Poly(ADP-ribose) Polymerases, RNA, Messenger, Tumor Cells, Cultured, Blotting, Western, Apoptosis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
